Akèy › Kansè (tout kalite) › Texas › Irving
Etid klinik pou Kansè (tout kalite) nan Irving, TX
15 etid pou Kansè (tout kalite) ap chèche patisipan nan sit nan ak bò kote Irving (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
REC-7735 in Participants With Solid Tumors
Ap rekriteFaz 1/2
- NEXT Oncology - Dallas, Irving
A Phase 1 Study of IM-1617 in Participants With Advanced Cancer
Ap rekriteFaz 1
- NEXT Dallas, Irving
Registry Study for Radiation Therapy Outcomes
Ap rekriteEtid obsèvasyon
- Texas Center for Proton Therapy, Irving
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Ap rekriteFaz 3
- US Oncology Research Investigational Products Center, Irving
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Ap rekriteFaz 1/2
- NEXT Dallas, Irving
A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001)
Ap rekriteFaz 1
- NEXT Oncology ( Site 0051), Irving
A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)
Ap rekriteFaz 1/2
- NEXT Oncology ( Site 1012), Irving
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
Ap rekriteFaz 1/2
- NEXT Oncology Dallas, Irving
A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors
Ap rekriteFaz 1
- NEXT Oncology Dallas, Irving
A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors
Ap rekriteFaz 1
- NEXT Dallas, Irving
Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TGW101 in Participants With Advanced Solid Tumors
Ap rekriteFaz 1
- NEXT Dallas, Irving
Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors
Ap rekriteFaz 1/2
- NEXT Oncology, Irving
A Study of ERAS-4001 in Patients With Advanced or Metastatic Solid Tumors.
Ap rekriteFaz 1
- NEXT Oncology, Irving
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
Ap rekriteFaz 1/2
- NEXT Dallas, Irving
Registry Study for Proton Therapy Clinical Outcomes and Long-Term Follow-up
Ap rekriteEtid obsèvasyon
- Texas Center for Proton Therapy, Irving
Etid Kansè (tout kalite) nan lòt vil
- Houston, TX121 etid
- New York City, NY110 etid
- Boston, MA86 etid
- Los Angeles, CA73 etid
- Nashville, TN65 etid
- Philadelphia, PA59 etid
- Durham, NC58 etid
- Washington, DC58 etid
- Chicago, IL51 etid
- Seattle, WA49 etid
- Atlanta, GA49 etid
- Arlington, VA48 etid
Lòt etid nan Irving
- Kansè Poumon ki pa ti selil22 etid
- Kansè kolorektal13 etid
- Kansè Metastatik11 etid
- Kansè pankreyas7 etid
- Kansè lestomak7 etid
- Karsinòm selil skuamèz tèt ak kou6 etid
- Kansè nan tete6 etid
- Kansè poumon selil ti6 etid
- Kansè poumon6 etid
- Kansè ovè5 etid
- Kansè Endomèt4 etid
- Kansè pwostat4 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.